Clinical development failure or delay
Pipeline value depends on positive preclinical and clinical results and timely advancement.
- Scope
- VT-1953, VT-1908, VB-1953
- Materiality
- high
Vyome Holdings, Inc
Vyome Holdings, Inc. is a U.S.-based clinical-stage specialty pharmaceutical company organized around a biotechnology pipeline and a legacy pharmaceutical products business. Its development programs focus on immune-inflammatory and rare diseases, including topical and ophthalmic candidates, while the pharmaceutical segment includes antifungal products and related licensing arrangements.
−3 265,6 %
68,4 %
−3 209,7 %
+24,4 %
1.99
1.06
| % | |
|---|---|
| Biotechnology pipeline | 0% Clinical and preclinical drug candidates for immune-inflammatory and rare diseases. |
| Pharmaceutical products | 100% Legacy antifungal products and related commercial pharmaceutical operations. |
| Licensing and collaboration rights | 0% Legacy licensing agreements and potential partnering arrangements around assets. |
The company’s biotechnology programs are aimed at patients with serious unmet medical needs, typically accessed through...
- Specialty physicians and patientsprimary
They use the pipeline therapies for rare, inflammatory, or dermatologic conditions where current options are limited.
- Healthcare providersprimary
They prescribe the antifungal products and influence adoption through treatment protocols.
- Clinical trial ecosystemprimary
Investigators, sites, and enrolled patients support development of VT-1953, VT-1908, and VB-1953.
- Licensing counterpartiessecondary
Partners such as Sun Pharma-related arrangements support legacy pharmaceutical economics.
Vyome Holdings is based in the United States, with a reported operating footprint spanning Cambridge, Massachusetts,...
- •Headquartered in the United States
- •Operations in Cambridge, MA and Princeton, NJ
- •Development presence in New Delhi, India
- •U.S.-India innovation corridor supports R&D execution
- •Geography is operational, not revenue-disclosed in the filing
The company’s strategy centers on advancing its lead clinical and preclinical programs toward regulatory milestones...
01
Advance VT-1953 into pivotal developmentshort-term
This is the lead program and the most advanced path to a potential commercial asset.
02
Progress the ophthalmology and acne pipelinemedium-term
Diversifies the pipeline across multiple specialty indications and reduces single-asset dependence.
03
Secure external funding and partnershipsshort-term
Clinical development requires capital and the company expects to rely on financing and collaborations.
Vyome’s business depends on successful clinical development, regulatory clearance, and the ability to finance a...
Capital raising and liquidity risk
The company expects to fund operations through equity, debt, and collaborations until product revenue exists.
- Scope
- Corporate funding needs
- Materiality
- high
Regulatory risk
Drug development requires FDA alignment on protocols, approvals, and labeling.
- Scope
- Pivotal trial and pre-IND programs
- Materiality
- high
Commercialization risk in legacy pharma
Antifungal products and licensing arrangements may not generate enough scale to support the business.
- Scope
- Pharmaceutical segment
- Materiality
- medium
Convertible promissory notes at fair value
Non-cash income or expense volatility
Derivative accounting for embedded features
Can materially affect reported results period to period
Stock-based compensation
Dilution and expense recognition
Business combination and merger accounting
Affects balance sheet and comparability
: 29.4.2026